PHARMANUTRA SIGLA UN NUOVO ACCORDO IN SVIZZERA E RAFFORZA LA PROPRIA PRESENZA IN EUROPA CENTRALE

Ci spiace, ma questo articolo è disponibile soltanto in Inglese Americano.

PharmaNutra S.p.A. announces that an agreement has been firmed with Fresenius Kabi Switzerland, a company of the German multinational Fresenius Kabi specialized in medicines and technologies for infusion, transfusion and clinical nutrition, used for the care of critically ill patients or those suffering from chronic diseases.

Thanks to this partnership, PharmaNutra strengthens its presence in the Swiss market, where the distribution of products based on Sucrosomial Iron® will start from the beginning of 2019 with the first two products, while other two products will be added in 2020 .

For PharmaNutra, this is a highly strategic agreement to further consolidate its presence in Central Europe. An important step, not only for the choice of an international partner with whom we already collaborate in other countries, but above all because Switzerland is recognized as one of the most important markets for the iron sector from a scientific and commercial point of view. Fresenius Kabi is a global colossus, leader in the field of nutrition and infusion therapy, and it also represents for PharmaNutra a partner of absolute value to quickly establish itself within the Swiss market, as it is happening in the new foreign countries in which the Group started to distribute its products.

The figures for the first half of 2018 confirmed that the SiderAL® brand products recorded an overall significant increase in terms of revenues (+ 25%), as well as, globally, in the first six months of the year the PharmaNutra Group further strengthened its presence on international markets with 44.3% turnover growth (from 3.4 million to 5 million euros). Those results are a further recognition of the SiderAL® products quality, but above all it confirms the scientific effectiveness of the Sucrosomial® Technology that the Group is preparing to introduce in the Swiss market with great prospects.

Andrea Lacorte, President of PharmaNutra, comments: “We are building a new alliance from a strategic and commercial point of view. An alliance with a premium partner that will allow us to strengthen our strategy in a market of absolute significance for the iron sector. Combining the scientific innovation of Ferro Sucrosomiale® with a capillary distribution throughout Switzerland, we will soon have very positive results in terms of sales”.